Plain-English translation of NCT05752552 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called designed to target a specific genetic change found in some advanced lung cancers. Researchers want to understand how safe the medication is and how your body processes it. The trial is recruiting people whose lung cancer has stopped responding to standard treatments and whose tumors carry a particular genetic mutation called MET exon 14 skipping.
Many people with advanced lung cancer eventually stop responding to available treatments, and their options become very limited. This medication was designed specifically to attack tumors with this particular genetic mutation, so this trial aims to see if it could offer a new hope for patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth once daily for 28 days in a cycle that repeats over 4 weeks. The trial has two parts: the first part carefully tests different dose levels in small groups of patients to find the safest dose, and the second part enrolls more patients at that selected dose to see if the medication works. You would need regular visits for blood tests, scans, and check-ins with your doctor to monitor how you're tolerating the treatment and whether your cancer is responding.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Belgium
France